Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 14.98M P/E - EPS this Y 95.00% Ern Qtrly Grth -
Income -11.83M Forward P/E -0.96 EPS next Y -48.90% 50D Avg Chg 12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -62.00%
Dividend N/A Price/Book 0.73 EPS next 5Y - 52W High Chg -99.00%
Recommedations 1.00 Quick Ratio 5.47 Shares Outstanding 4.91M 52W Low Chg 52.00%
Insider Own 38.21% ROA -45.76% Shares Float 4.66M Beta -0.66
Inst Own 1.98% ROE -86.09% Shares Shorted/Prior 26.56K/6.82K Price 0.55
Gross Margin - Profit Margin - Avg. Volume 380,464 Target Price 36.50
Oper. Margin - Earnings Date Mar 28 Volume 1,373,472 Change 9.69%
About NeuroBo Pharmaceuticals, Inc.

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

NeuroBo Pharmaceuticals, Inc. News
02/12/24 NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference
02/01/24 NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
01/18/24 NeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of DA-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
01/18/24 NRBO: Initiating Coverage of NeuroBo Pharmaceuticals, Inc.; Targeting the $30 Billion+ Obesity Market…
01/09/24 NeuroBo Pharmaceuticals Regains Compliance with Nasdaq Minimum Price Requirement
01/02/24 NeuroBo to Participate in Industry and Investor Conferences in January
12/28/23 NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
12/19/23 NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
12/15/23 Life Science Investor Forum: Presentations Now Available for Online Viewing
12/12/23 Life Science Investor Forum Agenda Announced for December 14th, 2023
12/01/23 NeuroBo to Participate in Investor Conferences in December
11/13/23 NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/06/23 NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
10/17/23 NeuroBo to Present at the H.C. Wainwright 7th Annual NASH Investor Conference
09/15/23 NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
08/14/23 NEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF EXECUTIVE OFFICER AND PRESIDENT
08/09/23 NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
08/03/23 NeuroBo Pharmaceuticals Receives First Site IRB Approval for its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
08/02/23 NeuroBo Pharmaceuticals Enters Into Term Sheet With MThera Pharma to Out-license NB-01
06/27/23 NeuroBo Pharmaceuticals' Novel GLP1R and GCGR Dual Agonist, DA-1726, Shown to Elicit Superior Weight Loss Efficacy Compared to Semaglutide and Tirzepatide in Preclinical Models
NRBO Chatroom

User Image pumpupthevolume5577 Posted - 3 days ago

$NRBO this is so undervalued with so much potential

User Image EJBB Posted - 3 days ago

$NRBO hoping this thing gives me generational wealth. 🤞🤞🤞

User Image Profit_Gainz Posted - 4 days ago

$NRBO how was this trading at 129,500?

User Image thestockthing Posted - 4 days ago

$NRBO I know y’all blocked him but the view hasn’t posted here in a while. Put on the belt.

User Image RollingDollar Posted - 4 days ago

$NRBO

User Image thestockthing Posted - 4 days ago

$NRBO nice ass chart.

User Image RollingDollar Posted - 4 days ago

$NRBO

User Image jonnyloitering Posted - 4 days ago

$NRBO Key Zone... Can it build support above 5.67?

User Image RollingDollar Posted - 4 days ago

$NRBO

User Image jonnyloitering Posted - 4 days ago

$NRBO Interesting action going on.

User Image Jw242 Posted - 5 days ago

$NRBO glad I bought back a load at $4.30 a week or so back. Pretty much paying just to see Broadview’s sweatpants in a wad

User Image ArcherRumsey Posted - 5 days ago

$BLND $NRBO Analyst price target for next week. https://beststock-trading-chatplatform.daytrading.network

User Image Manipulation13F Posted - 1 week ago

$NRBO 💎

User Image Doozio Posted - 1 week ago

$NRBO fook it! Chop chop huckleberries n it’s still so early in 🧠⏰

User Image jonnyloitering Posted - 1 week ago

$NRBO Covering before the long weekend. I'll take the spike. Maybe we'll see a couple more green candles before close at the 5.40ish range.

User Image GoodRunner Posted - 1 week ago

$NRBO I've got a price target of $80 for this and am in it until it goes over that.

User Image jonnyloitering Posted - 1 week ago

$NRBO Can it maintain above $5.08? It's a key level.

User Image RollingDollar Posted - 1 week ago

$NRBO

User Image Housatonic1864 Posted - 1 week ago

$COSM give us 🏃 like $NRBO

User Image ItsAlwaysGreen Posted - 1 week ago

$NRBO idk I got a good feeling 👀

User Image RockyShall Posted - 1 week ago

$NRBO gonna run soon keep an eye on it

User Image LesterBrandon88 Posted - 1 week ago

$NRBO 👌🍻🥂💰👀

User Image RollingDollar Posted - 1 week ago

$NRBO

User Image KnightMason Posted - 1 week ago

$NRBO just

User Image Stock_Titan Posted - 1 week ago

$NRBO NeuroBo Pharmaceuticals to Participate in the BIO CEO & Investor Conference https://www.stocktitan.net/news/NRBO/neuro-bo-pharmaceuticals-to-participate-in-the-bio-ceo-amp-investor-zmzyixsov19o.html

User Image newandimproveddonkeykong Posted - 2 weeks ago

@AndyYo I'm liking $ARQT, but maybe a little late. Also looking at $ESPR, $AQST, $NRBO, $MREO Tracking here: https://docs.google.com/spreadsheets/d/1JQdyAMmw-xKroFRMBGJWeCB55dDmcMhlcFJYVYYYdL0/edit?usp=sharing NIA

User Image CK2024 Posted - 2 weeks ago

$NRBO running soon!

User Image jcooptechit Posted - 2 weeks ago

**Positions Update** Swings: - $PCSA: $2.35 avg. Scaled 50% yesterday at $2.55, and swinging the rest. Under $2 stops me, but will add dips along the way. Momentum/Overnight: - $WNW: $1.34 avg. Tapped a PM high of $1.72 and consolidated $1.50s (above VWAP) strong to close out the day. Chinese New Years start on the 10th and expecting China tickers to have fireworks to close out the week. Over $1.78, the potential is massive here. Recently Closed: (past few trading sessions) - PCSA: $2.35 - $2.55 (50% scaled) - $VLCN: $3.20 - $3.45/$3.95 - $NRBO: $5.15 - $6.20 - $POL: $5.45 - $6.05

User Image Rachel20201 Posted - 2 weeks ago

$NRBO my trading platform reduced shares maximum position to 100 only 😳🔥😳

User Image jonnyloitering Posted - 2 weeks ago

$NRBO They tend to release news Thursday mornings... Maybe we have something incoming.

Analyst Ratings
Ladenburg Thalmann Buy Dec 7, 22
HC Wainwright & Co. Buy Feb 1, 21